What are the current guidelines for cervical cancer screening in Australia?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 7, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Current Cervical Cancer Screening Guidelines in Australia

In Australia, the current cervical cancer screening program recommends 5-yearly primary HPV testing for women aged 25-74 years, replacing the previous 2-yearly Pap test program for women aged 18-69 years. 1, 2

Core Recommendations

  • Screening begins at age 25 (regardless of sexual history or vaccination status) and continues until age 74 1, 2
  • Primary HPV testing is performed every 5 years, with partial genotyping for HPV 16/18 3, 2
  • Women who test positive for HPV 16/18 are directly referred for colposcopy due to higher risk 2
  • Women who test positive for other high-risk HPV types undergo liquid-based cytology triage testing 3, 2
  • Women with negative or low-grade cytology results and non-16/18 HPV are recommended for 12-month follow-up HPV testing 3, 2
  • Women who have had a total hysterectomy with removal of the cervix and no history of high-grade lesions do not require screening 4

Management Pathways

  • Women with HPV 16/18 positive results are referred directly to colposcopy regardless of cytology results 2
  • Women with other high-risk HPV types and high-grade cytology are referred to colposcopy 3, 2
  • Women with other high-risk HPV types and negative or low-grade cytology undergo a 12-month follow-up HPV test 3, 2
  • If the 12-month follow-up test is positive for any high-risk HPV type, referral for colposcopy is recommended 2

Special Considerations

  • HPV-vaccinated women follow the same screening recommendations as unvaccinated women 4, 5
  • Self-collection is available as an option for under-screened women (those who are at least two years overdue for screening) 6
  • Women who exit the program at age 74 should have had two negative HPV tests within the previous 10 years 5

Program Effectiveness

  • The transition from 2-yearly cytology to 5-yearly HPV testing is predicted to reduce cervical cancer incidence and mortality by 24-36% 3
  • Australia is projected to reach a cervical cancer incidence of fewer than 4 cases per 100,000 women by 2028, potentially eliminating cervical cancer as a public health problem 1
  • The combination of high HPV vaccination coverage and the renewed screening program puts Australia on track to be one of the first countries to eliminate cervical cancer 1

Common Pitfalls to Avoid

  • Continuing to screen women under age 25, which can lead to unnecessary interventions for lesions that would likely regress 4
  • Screening more frequently than every 5 years, which provides minimal additional benefit while increasing harms from false positives 7
  • Failing to offer self-collection to eligible under-screened women, which is an important strategy to increase participation 6
  • Referring women with non-16/18 HPV and low-grade cytology directly to colposcopy, which is not cost-effective and leads to unnecessary procedures 3

The Australian program's evidence-based approach balances the benefits of early detection with minimizing harms from over-screening and unnecessary procedures, while leveraging the country's high HPV vaccination rates to move toward cervical cancer elimination.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.